Inhaler monitoring company Adherium has named former Vectura CEO James Ward-Lilley as a director and Chairman of the Board after the recent death of Thomas Lynch, who had been Chairman since 2016. The company also promoted Mike Motion from Chief Commercial Officer, a position he had held since November 2019, to Chief Operating Officer. Prior to joining Vectura as … [Read more...] about Adherium appoints James Ward-Lilley as Chairman of the Board following the death of Thomas Lynch
News
FDA issues EUA allowing B. Braun infusion pumps to be used with nebulizers
German medical device company B. Braun Medical announced that the FDA has issued Emergency Use Authorization (EUA) of several of the company's infusion pumps for "tracheal delivery of continuous nebulized medications into a nebulizer to treat patients of all ages with or suspected of having the Coronavirus Disease 2019 (COVID-19) and to decrease the exposure of … [Read more...] about FDA issues EUA allowing B. Braun infusion pumps to be used with nebulizers
Health Canada approves clinical trial of Bausch Health’s Virazole ribavirin inhalation solution for COVID-19
Bausch Health announced that Health Canada has approved a clinical trial of the company's Virazole ribavirin inhalation solution for the treatment of respiratory distress in patients hospitalized with COVID-19, and the study is expected to begin within a few weeks. The company said that it is also discussing the possibility of similar studies with regulatory … [Read more...] about Health Canada approves clinical trial of Bausch Health’s Virazole ribavirin inhalation solution for COVID-19
DDL moving ahead with plans for December meeting, issues calls for papers, award entries
Organizers for the Drug Delivery to the Lungs (DDL) meetings say that they are provisionally moving ahead with DDL 2020, scheduled for December 9-11 at the Edinburgh International Conference Centre, and they have issued a call for papers and award entries. The organizers say, "Whilst we are very conscious of the ever changing situation around the world concerning … [Read more...] about DDL moving ahead with plans for December meeting, issues calls for papers, award entries
Nanoform appoints Miguel Calado as Chairman of the Board
Finnish nanoparticle engineering company Nanoform has announced the beginning of a year-long process that will conclude with Miguel Calado succeeding Rabbe Klemets as Chairman of the Board. Klemets will take on an advisory role. Calado is currently Vice Chairman of the Board; he will be succeeded in that role by non-executive board member, Mads Laustsen. Prior to … [Read more...] about Nanoform appoints Miguel Calado as Chairman of the Board
Proveris Scientific announces new hires
Aerosol testing specialist Proveris Scientific has announced two new hires: Lee Dalton has joined Proveris as Director of Sales for North America, and Juan Osvaldo Moliere Velez, a mechanical engineer, has joined the company's technical service team. Dalton was most recently Sales Manager, Applied Sciences for Swedish intrument company Biotage AB. He has … [Read more...] about Proveris Scientific announces new hires
Biohaven gets FDA approval for study of intranasal vazegepant for COVID-19
Biohaven Pharmaceutical said that the FDA has approved the company's IND for a Phase 2 study of its vazegepant intranasal calcitonin gene-related peptide (CGRP) receptor antagonist for the reduction of excessive immune response leading to lung injury in COVID-19 patients. Biohaven recently announced that it would advance vazegepant (BHV-3500) into Phase 3 development … [Read more...] about Biohaven gets FDA approval for study of intranasal vazegepant for COVID-19
Theravance Biopharma intends to begin clinical development of nebulized JAK inhibitor for COVID-19
Theravance Biopharma said that it has submitted a clinical trial application (CTA) to begin clinical development of its TD-0903 nebulized JAK inhibitor for prevention of cytokine storm, which can lead to acute respiratory distress syndrome (ARDS), in hospitalized patients with COVID-19. Theravance initially planned to develop TD-0903 for the prevention of graft … [Read more...] about Theravance Biopharma intends to begin clinical development of nebulized JAK inhibitor for COVID-19
TFF announces collaboration with the University of Georgia and UT Austin on dry powder universal flu vaccine
TFF Pharmaceuticals has announced a research collaboration deal with the University of Georgia’s Center for Vaccines and Immunology (CVI) and with the University of Texas at Austin (UT Austin) for testing of dry powder universal influenza vaccines formulated using TFF's thin film freezing technology. UT Austin will formulate CVI vaccines based on TFF's technology, and … [Read more...] about TFF announces collaboration with the University of Georgia and UT Austin on dry powder universal flu vaccine
Cipla announces results of Phase 3 study for generic of Advair Diskus
Cipla has announced that a Phase 3 study demonstrated therapeutic equivalence of its generic fluticasone propionate/salmeterol DPI (100/50 mcg) to Advair Diskus 100/50 mcg. The 15-month trial enrolled 1400 asthma patients in the US. Cipla Global CEO Umang Vohra commented, “I am extremely pleased with the successful completion of the Phase-3 clinical study of … [Read more...] about Cipla announces results of Phase 3 study for generic of Advair Diskus